Breaking News
Sort by:
Top Post
Taysha Gene Therapies Announces First Patient Dosed with TSHA-102 in the REVEAL Phase 1/2 Trial for the Treatment of Rett Syndrome
Taysha Gene Therapies, a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene […]
Zenshine Pharmaceuticals' ZX-7101A Met the Primary Endpoint of the Phase 2 Study for the Treatment of Acute Uncomplicated Influenza in Adults
On April 1st, 2023, during the First Infection Collaboration Forum of the Chinese National Center […]
MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
MyMD Pharmaceuticals, a clinical-stage biopharmaceutical company developing groundbreaking therapies for the treatment of serious and […]
Peptilogics to Present Data in Patients Undergoing DAIR for the Treatment of Periprosthetic Joint Infection at ECCMID 2023
Peptilogics, a clinical-stage biotechnology company, has completed the enrollment of a Phase 1b trial for […]
Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent
Lipella Pharmaceuticals, a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today announces […]
Astrocyte Announces Initiation of an Extended Infusion Phase 1B Study of AST-004 for Stroke and Traumatic Brain Injuries
Astrocyte Pharmaceuticals, a drug discovery and development company advancing novel cerebroprotective therapeutics for patients with […]
ECCMID 2023: Shionogi to Present Data Showing COVID-19 Symptom Recurrence is Not Associated with Ensitrelvir Treatment
Shionogi today announced that two late-breaking poster presentations featuring new results from the Phase 3 […]
Lynk Pharmaceuticals Announces Positive Results for LNK01003 in Phase I Trial in Healthy Subjects
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that it has recently completed phase I trials […]
First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Arrowhead Pharmaceuticals today announced that the first patient has been dosed in Takeda’s Phase 3 […]
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera
Silence Therapeutics, an experienced and innovative biotechnology company committed to transforming people’s lives by silencing […]
Vivani Medical Announces $1 Million NIH Grant Funding to Support Cortigent’s Ongoing Orion Clinical Study
Vivani Medical, an emerging biopharmaceutical company that develops miniaturized, subdermal implants has announced that the […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more